₹242.4
-0.66% today
· 30d +2.28%
as of 2026-09-04
Price · Daily Candles
“Jagsnapharm profit surges 33% YoY while sales growth remains modest.”
Jagsnapharm has shown strong Q4 FY26 net profit growth of +33.1% YoY, reaching ₹9 Cr, alongside a healthier operating profit growth of +24.76% YoY. However, quarterly revenue growth at +9.64% YoY remains in the single digits, and the annual revenue growth for FY26 was just +6.89%.
BULL CASE
+Net profit in Q4 FY26 rose by +33.1% YoY to ₹9 Cr, indicating strong profitability improvements.
+Operating profit also saw a significant increase of +24.76% YoY in Q4 FY26, with OPM improving by 2.54%.
+Promoter shareholding increased by 0.5% QoQ to 67.89% in Q4 FY26, while FIIs increased their stake by 0.32% to 2.44%, signaling confidence.
+The 3-year and 5-year Net Profit CAGR stands at 17.28% and 20.36% respectively, showcasing consistent long-term profit growth.
BEAR CASE
−Q4 FY26 revenue growth was a modest +9.64% YoY, and annual revenue growth for FY26 was only +6.89% YoY, indicating weaker top-line expansion.
−The stock is trading at a PE of 32.95, which is higher than its 5-year average of 20.36, suggesting a potentially rich valuation.
−ML predictions for Free Cash Flow (FCF) growth indicate a weak outlook, with all 1-year FCF predictions ranking below 0.3.
−Despite recent positive quarterly performance, the stock is down -1.77% over the last year and -31.38% off its 52-week high of ₹301.65.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-03-31
REVENUE
₹64 Cr
+9.64% YoY
NET PROFIT
₹9 Cr
+33.1% YoY
OPM
21.27%
+2.54pp YoY
EPS
₹1.25
PE 32.95
Intrinsic value · DCF: N/A — ML model predicts severe Δ FCF compression (h1=-50.0%, h2=-47.3%, h3=-46.0% of mktcap), driving projected FCF negative by year 3 despite healthy current FCF. Treating as forecast outlier rather than reporting a misleading ₹0 valuation. Use the Strategy Fit and ML sections instead.
◇ Sector Position
JAGSNPHARM's PE of 32.95 is below sector leaders like DIVISLAB (69.81) but above the more established DRREDDY (19.55) and ZYDUSLIFE (21.54), positioning it in the middle tier for valuation against peers.
PEERPEROCE %
JAGSNPHARM32.95—
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒
62
SCORE / 100
Overall
6-axis composite of the sections below.
Performance
POSITIVE
55
Valuation
FAIR
40
Growth
MUTED
38
Profitability
HIGH
75
Technicals
STRONG
77
Risk
LOW
90
Key Stats
TTM PE
32.95
P/B
5.28
52W HIGH
₹264.5
OFF HIGH
-8.36%
DIV YIELD
1.22%
MKT CAP
₹1634 Cr
◉ Active Signals
MACDBullish0.2035
RSI(14)Neutral57.04
⧉ Strategy Fit 🔒